Jon Napitupulu

CrazyBulk, a sports nutrition brand, has launched a 2026 marketing push positioning its “legal, non-hormonal” SARM-style supplements as safer...

Immunocore laid out a 2026 agenda centered on expanding its melanoma franchise and advancing its TCR bispecific platform beyond...

Cellectis has set 2026 as a catalyst-heavy year, centering on a pivotal phase 2 trial for its off-the-shelf CAR-T,...

ImmuCell posted preliminary 2025 results and a strategic reset. Fourth-quarter sales reached $7.6 million, down 1.6% year over year,...

Day One Biopharmaceuticals reported preliminary 2025 net product revenue of $155.4 million for Ojemda, up 172% year over year,...

CrazyBulk has launched a 2026 marketing and product push around “legal SARM-style” bulking stacks, pairing a detailed buyer’s guide...

Nicox has repaid all secured debt owed to Kreos Capital and secured up to €4 million in new unsecured...

CorMedix Therapeutics has consolidated its leadership bench as it scales into a multi-brand anti-infectives and hospital products company. The...

Collegium Pharmaceutical set 2026 guidance at $805–$825 million in net product revenue with adjusted EBITDA of $455–$475 million, anchored...

Alvotech disclosed two insider transactions filed with the Luxembourg financial regulator: ATP Holdings ehf., identified as a manager or...